Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 18, Number 6—June 2012

CME ACTIVITY

Pretransplant Fecal Carriage of Extended-Spectrum β-Lactamase–producing Enterobacteriaceae and Infection after Liver Transplant, France

Frédéric BertComments to Author , Béatrice Larroque, Catherine Paugam-Burtz, Federica Dondero, François Durand, Estelle Marcon, Jacques Belghiti, Richard Moreau, and Marie-Hélène Nicolas-Chanoine
Author affiliations: Hôpital Beaujon, Clichy, France (F. Bert, B. Larroque, C. Paugam-Burtz, F. Dondero, F. Durand, E. Marcon, J. Belghiti, R. Moreau, M.H. Nicolas-Chanoine); Université Paris VII Faculté de Médecine D. Diderot, Paris, France (C. Paugam-Burtz, F. Durand, J. Belghiti, M.H. Nicolas-Chanoine); INSERM U 773 Centre de Recherche Biomédicale Bichat-Beaujon, CRB3, Paris (F. Durand, R. Moreau, M.H. Nicolas-Chanoine)

Main Article

Table 1

Characteristics of 710 liver transplant recipients included in study of ESBLE pretransplant fecal carriage and posttransplant infection, France, January 2001–April 2010*

Characteristic Value
Age, y, mean ± SD 50 ± 11
Male sex 490 (69)
Viral hepatitis 261 (36.7)
Hepatocellular carcinoma 221 (31.1)
Alcoholism 196 (27.6)
Acute liver failure 74 (10.4)
Biliary disease 61 (8.6)
HIV infection 21 (3)
MELD score, mean ± SD 18 ± 9

*Values are no. (%) patients except as indicated. ESBLE, extended spectrum β-lactamase–producing Enterobacteriaceae; MELD, Model for End-stage Liver Disease.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO